Danoprevir

別名:ITMN-191, RG7227

Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2.

Danoprevir化学構造

CAS No. 850876-88-9

サイズ 価格(税別) 在庫状況
JPY 22000 国内在庫あり
JPY 37000 国内在庫あり

代表番号: 045-509-1970|電子メール:sales@selleck.co.jp
よく尋ねられる質問

文献中Selleckの製品使用例(22)

カスタマーフィードバック5

製品安全説明書

現在のバッチを見る: S118301 DMSO] 144 mg/mL] false] Ethanol] 144 mg/mL] false] Water] Insoluble] false 純度: 99.94%
99.94

Danoprevir関連製品

HCV Protease阻害剤の選択性比較

生物活性

製品説明 Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2.
特性 A peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV).
Targets
HCV NS3/4A protease
0.2 nM-3.5 nM
In Vitro
In vitro

Danoprevir (0.29 nM) inhibits the reference genotype 1 NS3/4A protease half-maximally, but a high dose of this compound (10 μM) shows no appreciably inhibition in a panel of 79 proteases, ion channels, transporters, and cell surface receptors. It remains bound to and inhibits NS3/4A for more than 5 hours after its initial association. This chemical (45 nM) eliminates a patient-derived HCV genotype 1b replicon from hepatocyte-derived Huh7 cells with an EC50 of 1.8 nM. In HCV subgenomic replicon cell lines containing the individual mutations, V36M, R109K, and V170A substitutions confer little or no resistance to it, but the R155K substitution confers a high level (62-fold increase) of resistance to this compound. In Huh7.5 cells transfected with chimeric recombinant virus, it shows antiviral inhibition effects against HCV genotypes 1, 4 and 6 with IC50 of 2-3 nM, which are >100-fold lower than genotypes 2/3/5 (280-750 nM).

Kinase Assay Continuous fluorescent resonance energy transfer (FRET) assay
The assay buffer contains 25 μM NS4A peptide, 50 mM Tris-HCl, pH 7.5, 15% vol/vol, 10 mM dithiothreitol, and 0.5 μM QXL520-labeled FRET substrate {Ac-DE-Dap(QXL520)-EE-Abu-ψ-[COO]-AS-Cys(5-FAMsp)-NH2}. K2040 enzyme (50 pM) is added to initiate the reaction. Reactions are set up in black 96-well plates, and fluorescence data is collected. Control reactions lacking inhibitors and enzyme are included. Initial rates are calculated from the linear phase of the reaction (up to 1 hour) and are used to obtain IC50. Recovery of activity from preformed this compound-NS3/4A complex is assessed by preincubating 10 nM NS3/4A with a two-fold excess of this chemical in 1× assay buffer for 15 min, followed by a rapid 200-fold dilution of the preformed complex into assay buffer containing substrate. A control reaction with the same final conditions without preincubation of NS3/4A and this compound is initiated by the addition of enzyme to an otherwise-complete reaction mixture. Additional control reactions lack either this chemical or NS3. The progress of the reactions is followed over 5 hours.
細胞実験 細胞株 Huh7 cells harboring HCV replicon
濃度 5 pM - 100 nM
反応時間 48 hours
実験の流れ

Serially diluted Danoprevir is added to Huh7 cells harboring the K2040 replicon 1 day after cell plating. For antiviral assays, after a 48-hour incubation, intracellular RNA is extracted, and the level of HCV replicon RNA is quantified by reverse transcription (RT)-PCR assay with the primers (5'-CACTCCCCTGTGAGGAACTACTG-3' and 5'-AGGCTGCACGACACTCATACT-3') and a probe (5'-6-FAM-CTTCACGCAGAAAGCGTCTAGCCATGG-MGBNFQ-3' using an ABI Prism 7900 sequence detection system. Here, FAM is 6-carboxyfluorescin and MGBNFQ is a molecular-groove binding non-fluorescence quencher specific to the HCV 5' untranslated region. Single-tube reactions are performed using the TaqMan Gold RT-PCR kit. Triplicate reactions for the RNA standards and samples are performed in 50 μL with 5 μL intracellular RNA (50 ng). RT is carried out at 48 °C for 30 min followed by 10 min at 95 °C. The PCR is run as follows: 15 seconds at 95 °C and 1 min at 60 °C for 40 cycles. Each RNA concentration is determined in triplicate. The absolute concentration of replicon RNA is calculated based on its signal relative to that of a standard curve generated by known concentrations of an in vitro-transcribed RNA corresponding to a genotype 1b 5' untranslated region. Replicon levels in the presence of this compound are fitted to a four-parameter logistic function to obtain EC50.

In Vivo
In Vivo

Danoprevir (30 mg/kg) administered to rats or monkeys shows that its concentrations in liver 12 hours after dosing exceed the concentration of this compound required to eliminate replicon RNA from cells.

動物実験 動物モデル Sprague-Dawley rats, Cynomolgus monkeys
投与量 30 mg/kg
投与経路 Oral gavage
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01714154 Completed
Healthy Volunteer
Hoffmann-La Roche
November 2012 Phase 1
NCT01592318 Completed
Healthy Volunteer
Hoffmann-La Roche
May 2012 Phase 1
NCT01588002 Completed
Healthy Volunteer
Hoffmann-La Roche
April 2012 Phase 1
NCT01519336 Completed
Healthy Volunteer
Hoffmann-La Roche
February 2012 Phase 1
  • https://pubmed.ncbi.nlm.nih.gov/18824605/
  • https://pubmed.ncbi.nlm.nih.gov/18637752/
  • https://pubmed.ncbi.nlm.nih.gov/21480315/

化学情報

分子量 731.83 化学式

C35H46FN5O9S

CAS No. 850876-88-9 SDF Download Danoprevir SDFをダウンロードする
Smiles CC(C)(C)OC(=O)NC1CCCCCC=CC2CC2(NC(=O)C3CC(CN3C1=O)OC(=O)N4CC5=C(C4)C(=CC=C5)F)C(=O)NS(=O)(=O)C6CC6
保管

In vitro
Batch:

DMSO : 144 mg/mL ( (196.76 mM); 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Ethanol : 144 mg/mL

Water : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください